Role of Surgery in Multimodality Treatment for Non-small Cell Lung Cancer;Current Status and Future Perspectives

Toshiyuki Shima, Kyohei Masai, Tomoyuki Hishida, Kaoru Kaseda, Kohei Hashimoto, Yusuke Takahashi, Takashi Otsuka, Hisao Asamura

Research output: Contribution to journalReview article

Abstract

Recent improvement of outcomes for resected non-small cell lung cancer (NSCLC) has been contributed not only by increased detection of early-stage disease and improvement of preoperative diagnosis/perioperative management but also by improvement of multimodality treatment. The introduction of newly developed systemic therapies including molecular targeted agents and immune checkpoint inhibitors dramatically changed clinical outcomes of advanced NSCLC. Accordingly, the role of surgery during the multimodality treatment will be changed more than ever. In this article, we overviewed the current status of the multimodality treatment for clinical stageⅢ (N2)disease and postoperative adjuvant therapy and discussed the role of surgery during these situations. We also discussed the future perspectives of the role of surgery during the multimodality treatment for advanced NSCLC.

Original languageEnglish
Pages (from-to)244-248
Number of pages5
JournalKyobu geka. The Japanese journal of thoracic surgery
Volume71
Issue number4
Publication statusPublished - 2018 Apr 1

Fingerprint

Non-Small Cell Lung Carcinoma
Molecular Targeted Therapy
Therapeutics
Early Diagnosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Role of Surgery in Multimodality Treatment for Non-small Cell Lung Cancer;Current Status and Future Perspectives. / Shima, Toshiyuki; Masai, Kyohei; Hishida, Tomoyuki; Kaseda, Kaoru; Hashimoto, Kohei; Takahashi, Yusuke; Otsuka, Takashi; Asamura, Hisao.

In: Kyobu geka. The Japanese journal of thoracic surgery, Vol. 71, No. 4, 01.04.2018, p. 244-248.

Research output: Contribution to journalReview article

@article{d8832f2d5ac14cf68dcbd626142fbf5b,
title = "Role of Surgery in Multimodality Treatment for Non-small Cell Lung Cancer;Current Status and Future Perspectives",
abstract = "Recent improvement of outcomes for resected non-small cell lung cancer (NSCLC) has been contributed not only by increased detection of early-stage disease and improvement of preoperative diagnosis/perioperative management but also by improvement of multimodality treatment. The introduction of newly developed systemic therapies including molecular targeted agents and immune checkpoint inhibitors dramatically changed clinical outcomes of advanced NSCLC. Accordingly, the role of surgery during the multimodality treatment will be changed more than ever. In this article, we overviewed the current status of the multimodality treatment for clinical stageⅢ (N2)disease and postoperative adjuvant therapy and discussed the role of surgery during these situations. We also discussed the future perspectives of the role of surgery during the multimodality treatment for advanced NSCLC.",
author = "Toshiyuki Shima and Kyohei Masai and Tomoyuki Hishida and Kaoru Kaseda and Kohei Hashimoto and Yusuke Takahashi and Takashi Otsuka and Hisao Asamura",
year = "2018",
month = "4",
day = "1",
language = "English",
volume = "71",
pages = "244--248",
journal = "Japanese Journal of Thoracic Surgery",
issn = "0021-5252",
publisher = "Nankodo Co., Ltd.",
number = "4",

}

TY - JOUR

T1 - Role of Surgery in Multimodality Treatment for Non-small Cell Lung Cancer;Current Status and Future Perspectives

AU - Shima, Toshiyuki

AU - Masai, Kyohei

AU - Hishida, Tomoyuki

AU - Kaseda, Kaoru

AU - Hashimoto, Kohei

AU - Takahashi, Yusuke

AU - Otsuka, Takashi

AU - Asamura, Hisao

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Recent improvement of outcomes for resected non-small cell lung cancer (NSCLC) has been contributed not only by increased detection of early-stage disease and improvement of preoperative diagnosis/perioperative management but also by improvement of multimodality treatment. The introduction of newly developed systemic therapies including molecular targeted agents and immune checkpoint inhibitors dramatically changed clinical outcomes of advanced NSCLC. Accordingly, the role of surgery during the multimodality treatment will be changed more than ever. In this article, we overviewed the current status of the multimodality treatment for clinical stageⅢ (N2)disease and postoperative adjuvant therapy and discussed the role of surgery during these situations. We also discussed the future perspectives of the role of surgery during the multimodality treatment for advanced NSCLC.

AB - Recent improvement of outcomes for resected non-small cell lung cancer (NSCLC) has been contributed not only by increased detection of early-stage disease and improvement of preoperative diagnosis/perioperative management but also by improvement of multimodality treatment. The introduction of newly developed systemic therapies including molecular targeted agents and immune checkpoint inhibitors dramatically changed clinical outcomes of advanced NSCLC. Accordingly, the role of surgery during the multimodality treatment will be changed more than ever. In this article, we overviewed the current status of the multimodality treatment for clinical stageⅢ (N2)disease and postoperative adjuvant therapy and discussed the role of surgery during these situations. We also discussed the future perspectives of the role of surgery during the multimodality treatment for advanced NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=85063695130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063695130&partnerID=8YFLogxK

M3 - Review article

VL - 71

SP - 244

EP - 248

JO - Japanese Journal of Thoracic Surgery

JF - Japanese Journal of Thoracic Surgery

SN - 0021-5252

IS - 4

ER -